Early increase of the synaptic blood marker β-synuclein in asymptomatic autosomal dominant Alzheimer's disease.

ABSTRACT:

Introduction

β-synuclein is a promising blood marker to track synaptic degeneration in Alzheimer's disease (AD) but changes in preclinical AD are unclear.

Methods

We investigated serum β-synuclein in 69 cognitively unimpaired mutation non-carriers, 78 cognitively unimpaired AD mutation carriers (asymptomatic AD), and 31 symptomatic mutation carriers from the Dominantly Inherited Alzheimer Network.

Results

β-synuclein levels were already higher in asymptomatic AD mutation carriers compared to non-carriers and highest in symptomatic carriers. Longitudinal trajectories and correlation analyses indicated that β-synuclein levels start to rise after amyloid deposition preceding axonal degeneration, brain atrophy and hypometabolism, and cognitive decline. β-synuclein levels

SUBMITTER: Oeckl P 

PROVIDER: S-EPMC11982912 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature